Very important development: FDA approves first drug

New Post Public Reply Private Reply Replies (0) Message Board
Jerseyfish
488
Very important development:

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy
For Immediate Release
June 25, 2018

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.

CBD is a chemical component of the Cannabis sativa plant, more commonly known as marijuana. However, CBD does not cause intoxication or euphoria (the “high”) that comes from tetrahydrocannabinol (THC).

It is THC (and not CBD) that is the primary psychoactive component of marijuana.

“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies. And, the FDA is committed to this kind of careful scientific research and drug development,” said FDA Commissioner Scott Gottlieb, M.D. “Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients. Because of the adequate and well-controlled clinical studies that supported this approval, prescribers can have confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes. We’ll continue to support rigorous scientific research on the potential medical uses of marijuana-derived products and work with product developers who are interested in bringing patients safe and effective, high quality products. But, at the same time, we are prepared to take action when we see the illegal marketing of CBD-containing products with serious, unproven medical claims. Marketing unapproved products, with uncertain dosages and formulations can keep patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”

Dravet syndrome is a rare genetic condition that appears during the first year of life with frequent fever-related seizures (febrile seizures). Later, other types of seizures typically arise, including myoclonic seizures (involuntary muscle spasms). Additionally, status epilepticus, a potentially life-threatening state of continuous seizure activity requiring emergency medical care, may occur. Children with Dravet syndrome typically experience poor development of language and motor skills, hyperactivity and difficulty relating to others.

Lennox-Gastaut syndrome begins in childhood. It is characterized by multiple types of seizures. People with Lennox-Gastaut syndrome begin having frequent seizures in early childhood, usually between ages 3 and 5. More than three-quarters of affected individuals have tonic seizures, which cause the muscles to contract uncontrollably. Almost all children with Lennox-Gastaut syndrome develop learning problems and intellectual disability. Many also have delayed development of motor skills such as sitting and crawling. Most people with Lennox-Gastaut syndrome require help with usual activities of daily living.

“The difficult-to-control seizures that patients with Dravet syndrome and Lennox-Gastaut syndrome experience have a profound impact on these patients’ quality of life,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “In addition to another important treatment option for Lennox-Gastaut patients, this first-ever approval of a drug specifically for Dravet patients will provide a significant and needed improvement in the therapeutic approach to caring for people with this condition.”

Epidiolex’s effectiveness was studied in three randomized, double-blind, placebo-controlled clinical trials involving 516 patients with either Lennox-Gastaut syndrome or Dravet syndrome. Epidiolex, taken along with other medications, was shown to be effective in reducing the frequency of seizures when compared with placebo.

The most common side effects that occurred in Epidiolex-treated patients in the clinical trials were: sleepiness, sedation and lethargy; elevated liver enzymes; decreased appetite; diarrhea; rash; fatigue, malaise and weakness; insomnia, sleep disorder and poor quality sleep; and infections.

Epidiolex must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks. As is true for all drugs that treat epilepsy, the most serious risks include thoughts about suicide, attempts to commit suicide, feelings of agitation, new or worsening depression, aggression and panic attacks. Epidiolex also caused liver injury, generally mild, but raising the possibility of rare, but more severe injury. More severe liver injury can cause nausea, vomiting, abdominal pain, fatigue, anorexia, jaundice and/or dark urine.

Under the Controlled Substances Act (CSA), CBD is currently a Schedule I substance because it is a chemical component of the cannabis plant. In support of this application, the company conducted nonclinical and clinical studies to assess the abuse potential of CBD.

The FDA prepares and transmits, through the U.S. Department of Health and Human Services, a medical and scientific analysis of substances subject to scheduling, like CBD, and provides recommendations to the Drug Enforcement Administration (DEA) regarding controls under the CSA. DEA is required to make a scheduling determination.

The FDA granted Priority Review designation for this application. Fast-Track designation was granted for Dravet syndrome. Orphan Drug designation was granted for both the Dravet syndrome and Lennox-Gastaut syndrome indications.

The FDA granted approval of Epidiolex to GW Research Ltd.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Rocky Mountain High Brands, Inc. (RMHB) Stock Research Links

RMHB Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 0

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 138

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 39

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 23

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Worker Pullback Is a Cost Problem Employers Ignore

Updated Category News Views 13

Somewhere between a job description and an unpaid favor, a lot of corporate productivity appears to be quietly leaking out. MyPerfectResume’s July 2026 survey of 1,000 U.S. workers says 78% have intentionally done only the minimum needed to keep their jobs at least once. That is not a cute workplace-culture headline. It is a warning flare about discretionary...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 52

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Chargeback AI Still Has a Costly Last-Mile Problem

Updated Category News Views 41

A corrected headline is a small wrinkle, but the underlying chargeback mess is not. Chargeflow and Juniper Research surveyed 121 senior executives at U.S. and U.K. businesses with at least $100 million in annual gross merchandise value, and the useful takeaway is painfully clear: merchants are putting AI on the label without rebuilding the machinery underneath. That...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 49

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading

Top 5 Most Recently Viewed Articles

Garanti BBVA Partners with Ripple and IBM for Secure Crypto Trading

Updated Category News Views 110

Garanti BBVA's Strategic Collaboration Garanti BBVA Kripto has formed a partnership with Ripple and IBM to enhance its digital asset trading platform, prioritizing security and performance. After a pilot phase that showcased effective technology integration, the bank is set to expand the offering to its full customer base, assuring its commitment to top-tier financial...

Continue Reading
Understanding Current Market Sentiment Amidst Tariff Concerns

Updated Category News Views 469

Market Sentiment and Tariffs' Influence Recently, there has been a noticeable shift in market sentiment, reflecting a more bearish outlook. Investors are understandably concerned about the impeding implications of tariffs and their impact on economic growth. This situation invites a closer examination of how sentiment plays a crucial role in market trends and potential...

Continue Reading
Marriott International Announces Exciting New Ritz-Carlton Hotel

Updated Category News Views 254

Marriott International Expands to Xiamen with The Ritz-Carlton Marriott International, Inc. has recently made a significant move in the hospitality sector by entering into an agreement with Xiamen Green Development Investment Group to introduce The Ritz-Carlton brand to Xiamen Island. This expansion showcases Marriott's commitment to delivering luxury services paired with...

Continue Reading
Jencap Shines in Insurance Leadership, Gains Recognition

Updated Category News Views 34

Breaking Down Jencap's Accolade In a crowded insurance landscape, getting noticed is no small feat. Well, Jencap just nabbed a recognition that places it in the industry's spotlight. According to Insurance Business America's latest annual report, Jencap shines as a 5-Star Program Administrator. This recognition didn’t just fall into their lap; it’s a nod that industry...

Continue Reading
Global Insights into the Air Quality Control Systems Market

Updated Category News Views 329

Understanding the Air Quality Control Systems Market The air quality control systems (AQCS) market is experiencing significant growth and is projected to reach a remarkable valuation of $195.1 billion by 2032. As reported, the market had a value of $105.2 billion in 2023, showing a promising compound annual growth rate (CAGR) of 6.8% during the period from 2024 to 2032....

Continue Reading